Covidien Gains Barrett’s Esophagus Ablation Device Via Barrx Acquisition
This article was originally published in The Gray Sheet
Deal worth $325 million bolsters Covidien’s energy-based product offerings with Barrx Medical’s radiofrequency energy-based HaloFlex system for preventing esophageal cancer.
You may also be interested in...
The $860 million purchase agreement will give Covidien the dominant capsule endoscopy platform on the market as the company hopes for FDA approval this year of PillCam COLON 2 as a less invasive alternative for patients who are unable to undergo a colonoscopy.
Acquired iLogic system includes planning and navigation software that generates three-dimensional images using patient CT scans, and disposable catheter-based tools for navigation and biopsy.
Clot removal device gains 510(k) clearance earlier than expected, will compete with Stryker’s Merci clot retrieval system.